Highly multiplexed spatial analysis of tumor tissue is necessary to improve understanding of anti-tumor immunity. Moreover, spatial interrogation of protein and nucleic acid simultaneously could better characterize immune cell subsets as targets such as cytokines and chemokines are difficult to detect by immunohistochemistry (IHC). NanoString's Digital Spatial Profıling (DSP) technology can detect and quantify proteins and RNA at highly multiplexed levels. We compared DSP to flow cytometry (FCM), IHC and in-situ hybridization (ISH) to assess its sensitivity and specificity. A pilot study was also performed to assess the DSP performance in 10 non-small cell lung cancer (NSCLC) FFPE samples, looking at the prevalence and distribution of immune cell subsets, cytokines, chemokines and tumor cells.
 To describe the function and technical validity of the Nanostring DSP platform by comparison to established methods of flow cytometry, chromogenic immunohistochemistry and in-situ hybridization for both proteins and RNA targets  Use high dimensional analysis tools to explore the data generated on the NSCLC pilot study at both a cohort and sample level ❖ Nanostring DSP enables high level multiplexing through liberation and enumeration of oligomer tags from primary antibodies or RNA probes in user-defined regions of interest (ROI) ❖ Barcodes consisting of a ssDNA backbone annealed to fluorescently-labeled ssRNA fragments in a unique sequence are conjugated to primary antibodies or nucleic acid probes via a UV-cleavable linker ❖ Following a pH 6.0 citrate antigen retrieval, an FFPE tissue sample is stained with a master mix including fluorescently-labeled and oligo-conjugated antibodies, visualized and ROIs are selected ❖ A 365nm UV beam successively illuminates ROIs liberating reporter oligos into wells of a 96-well plate.
Oligos from individual ROI are collected and counted on the nCounter platform. 
ABSTRACT RESULTS

CONCLUSIONS
Samples ID
❖ We find Nanostring DSP to be a highly reproducible method for prevalence estimation of higher abundance protein targets in human FFPE tissues with good correlation to established methods of immunohistochemistry and flow cytometry.
❖ RNA detection in clinical samples is more challenging. This could be due to RNA preservation in FFPE samples, sensitivity of the RNA assay as well as performance of the probes used. Methods to increase probe performance and sensitivity are currently being explored.
❖ In a clinical pilot study, high dimensional analysis of protein and a minority of RNA targets on adjacent tissue sections can generate tumor-or patient-specific signatures allowing classification of the tumor immune status (i.e. "hot" or "cold") as well as localization of immune cell subsets (stromal vs tumoral).
 DSP counts for 29 protein targets from 24 identical ROIs on serial sections for 10 cases were collected on separate runs. Counts for each ROI were compared between serial sections  Reproducibility was good to excellent for 20/29 targets (mean R 2 = 0.70 -0.92), fair for 8/29 (R 2 = 0.65 -0.52) and poor for 1/29 (R 2 = 0.38).
 RNA is detectable by DSP above background in the minority of ROIs for all targets. Comparison to protein counts for corresponding ROIs shows weak correlation of prevalence in both tumor and stromal ROIs  RNAScope ISH was performed for 16 markers (TGF-β1, 2, 3, CD45, CD20, CX3CL1, CXCL10, CXCL11, CCL2, CCL7, CXCL8, PD-L1, PD1, TIGIT and CD3) across a subset of 5 cases. RNAScope confirmed RNA integrity (PPIB strong positive) for all samples and suggests several possibilities for impaired detection including weak (CD3) or absent expression (TGF-B targets), patchy expression/sampling error (CXCL9-11) 
